EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
Selection, Procurement and Distribution
LEONOR GOMEZ-SAYAGO, INMACULADA LOMARES MANZANO, LUCIA JIMENEZ PICHARDO
Biosimilar medicines have demonstrated their bioequivalence with the original biologic and there is ample scientific evidence to support this.
Our Hospital had a degree of implementation of biosimilars of 8,16% (the lowest in its autonomous community), so it was decided to develop an intervention plan to increase the use of biosimilars and improve this indicator.
Develop a plan to increase the use of biosimilar medicines in a tertiary hospital.
It was decided to intervene on these drugs that had commercialized biosimilar drugs: etanercept, adalimumab, trastuzumab, bevacizumab, enoxaparin, epoetin. For the introduction of biosimilars of etanercept and adalimumab, the medical records of all patients with these prescriptions were reviewed and all those that were prescribed by active ingredient and not by brand-name drug, were changed to a biosimilar medication after consensus with the patients. For the new prescriptions of these drugs and of enoxaparin, trastuzumab, and bevacizumab, a document was prepared supported by the medical direction of our Hospital that would start with biosimilar molecules. Regarding epoetin, in our hospital we had epoetin beta that does not have a biosimilar, so it was decided, agreeing with oncology and hematology and based on the evidence, to change the molecule to epoetin alfa with its biosimilar medicine.
The degree of introduction of biosimilars was measured with the formula: nº Definid daily dose of biosimilar drugs dispensed/nº Definid daily dose of biosimilar drugs dispensed+Definid daily dose of the original biologic *100.
Before the implementation of the protocol for the introduction of biosimilars, the degree of introduction was 8,16%, 3 months after implementation the result had reached 21,10% and at 6 months it was 30%. This represents an economic impact of 286.295,53 € per year in savings.
The implementation of protocols agreed with the prescribers for the introduction of biosimilars should be a common practice of the hospital pharmacists to contribute to the sustainability of the health system.
